Powered by Max Banner Ads
The sales registered by Slovenia’s Krka pharmaceutical group totaled EUR 47 M last year, down from EUR 48.6 M in 2011, however the local market remained on first place for the group in South-East Europe, a company report shows, Mediafax informs. In its report at nine months Krka explained the sales drop through the restrictions placed on the distribution of Bilobil, one of the company’s most important products on the Romanian market. Croatia is the group’s second-largest market in the region, the Slovenian group reporting sales of EUR 35.2 M there. According to the data presented by Cegedim Romania, a market analysis and survey company, Krka is on 12th place in the rankings of pharmaceutical companies in Romania, having a market share of 2.4 per cent.